157 related articles for article (PubMed ID: 17450522)
41. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.
Schönthal AH; Chen TC; Hofman FM; Louie SG; Petasis NA
Expert Opin Investig Drugs; 2008 Feb; 17(2):197-208. PubMed ID: 18230053
[TBL] [Abstract][Full Text] [Related]
42. Up-regulation of p53 and mitochondrial signaling pathway in apoptosis by a combination of COX-2 inhibitor, Celecoxib and Dolastatin 15, a marine mollusk linear peptide in experimental colon carcinogenesis.
Piplani H; Vaish V; Rana C; Sanyal SN
Mol Carcinog; 2013 Nov; 52(11):845-58. PubMed ID: 22623379
[TBL] [Abstract][Full Text] [Related]
43. Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer.
Shi H; Jiang J; Ji J; Shi M; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Lett; 2014 Jul; 349(2):128-35. PubMed ID: 24746899
[TBL] [Abstract][Full Text] [Related]
44. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens.
Swamy MV; Cooma I; Reddy BS; Rao CV
Int J Oncol; 2002 Apr; 20(4):753-9. PubMed ID: 11894121
[TBL] [Abstract][Full Text] [Related]
45. Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer.
Halamka M; Cvek J; Kubes J; Zavadova E; Kominek P; Horacek J; Dusek L; Feltl D
Oral Oncol; 2011 Aug; 47(8):763-7. PubMed ID: 21696999
[TBL] [Abstract][Full Text] [Related]
46. [Inhibitive effect of celecoxib combined with tegafur gimeracil oteracil potassium on the growth of xenograft tumor of gastric cancer in nude mice].
Meng C; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 May; 29(5):458-61. PubMed ID: 23643260
[TBL] [Abstract][Full Text] [Related]
47. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Mutter R; Lu B; Carbone DP; Csiki I; Moretti L; Johnson DH; Morrow JD; Sandler AB; Shyr Y; Ye F; Choy H
Clin Cancer Res; 2009 Mar; 15(6):2158-65. PubMed ID: 19276291
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101.
Murakami K; Sakukawa R; Sano M; Hashimoto A; Shibata J; Yamada Y; Saiki I
Clin Cancer Res; 1999 Sep; 5(9):2304-10. PubMed ID: 10499597
[TBL] [Abstract][Full Text] [Related]
49. Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
Merchan JR; Jayaram DR; Supko JG; He X; Bubley GJ; Sukhatme VP
Int J Cancer; 2005 Jan; 113(3):490-8. PubMed ID: 15455390
[TBL] [Abstract][Full Text] [Related]
50. Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells.
van Heumen BW; Roelofs HM; Te Morsche RH; Marian B; Nagengast FM; Peters WH
Exp Cell Res; 2012 Apr; 318(7):819-27. PubMed ID: 22366264
[TBL] [Abstract][Full Text] [Related]
51. Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells.
Bocca C; Bozzo F; Cannito S; Parola M; Miglietta A
Mol Carcinog; 2012 Oct; 51(10):783-95. PubMed ID: 21882253
[TBL] [Abstract][Full Text] [Related]
52. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
Yanase K; Yoshiji H; Ikenaka Y; Noguchi R; Kitade M; Kaji K; Yoshii J; Namisaki T; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
Oncol Rep; 2007 Feb; 17(2):441-6. PubMed ID: 17203185
[TBL] [Abstract][Full Text] [Related]
53. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.
Kase S; Kubota T; Watanabe M; Furukawa T; Tanino H; Ishibiki K; Teramoto T; Kitajima M
Anticancer Res; 1993; 13(2):369-73. PubMed ID: 8517649
[TBL] [Abstract][Full Text] [Related]
54. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.
Buchanan FG; Holla V; Katkuri S; Matta P; DuBois RN
Cancer Res; 2007 Oct; 67(19):9380-8. PubMed ID: 17909047
[TBL] [Abstract][Full Text] [Related]
55. [Celecoxib induces apoptosis and inhibits angiogenesis in gastric cancer].
Ran JT; Zhou YN; Tang CW; Lu JR; Wu J; Lu H; Yang GD
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):448-51. PubMed ID: 19024521
[TBL] [Abstract][Full Text] [Related]
56. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Hackert T; Ryschich E; Jäger D; Büchler MW; Märten A
J Immunother; 2008 Jan; 31(1):28-33. PubMed ID: 18157009
[TBL] [Abstract][Full Text] [Related]
57. Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor.
Xu X; Jiang M; Zhang Y; Bi Y; Han M
Mol Med Rep; 2015 Jan; 11(1):289-94. PubMed ID: 25333891
[TBL] [Abstract][Full Text] [Related]
58. Antiproliferative effects of rapamycin and celecoxib in angiosarcoma cell lines.
Bundscherer A; Vogt T; Köhl G; Landthaler M; Hafner C
Anticancer Res; 2010 Oct; 30(10):4017-23. PubMed ID: 21036716
[TBL] [Abstract][Full Text] [Related]
59. Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts.
Kaneko S; Kaneko M; Fukushima T
Int J Clin Oncol; 2013 Feb; 18(1):116-25. PubMed ID: 22127347
[TBL] [Abstract][Full Text] [Related]
60. SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts.
Xie Y; Chen S; Wang CH; Tang CW
Cancer Biol Ther; 2011 Jul; 12(1):86-92. PubMed ID: 21532334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
